Oracle Corp. (NASDAQ: ORCL) has announced that it will acquire ClearTrial, a maker of cloud-based Clinical Trial Operations applications for an undisclosed sum. The transaction is expected to close in the first half of this year. The companies will continue to operate separately until the transaction is closed according to the Oracle announcement.
ClearTrial’s clinical trial applications “will add leading budgeting, forecasting, and analytics capabilities that help plan, source, and track clinical projects,” according to an Oracle overview of the transaction. Oracle plans to integrate ClearTrial’s solutions into its Health Sciences applications portfolio.
Oracle shares are trading down fractionally at $29.34 in a 52-week range of $24.72-$36.50.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.